Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 single-arm multicenter study of crovalimab in adults and adolescents with atypical hemolytic uremic syndrome
MOH_2021-12-06_010446Phase 3Recruiting
- Sponsor
- Roche
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of crovalimab in atypical hemolytic uremic syndrome (aHUS) (3 cohorts), sponsored by Roche. Primary endpoint: Complete TMA response through Week 24 in treatment-naive patients. Started Oct 2021; status: recruiting.
02
Drugs
crovalimab
03
Conditions
atypical hemolytic uremic syndrome (aHUS)
Beyond the preview
Go deeper on MOH_2021-12-06_010446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-12-06_010446.